Angiogenesis News and Research RSS Feed - Angiogenesis News and Research

Angiogenesis is blood vessel formation. Tumor angiogenesis is the growth of new blood vessels that tumors need to grow. This is caused by the release of chemicals by the tumor.
Using acidity to detect cancer

Using acidity to detect cancer

Normally, tissues demonstrate a slightly acidic intracellular pH (pHi) and slightly alkaline extracellular pH (pHe). However, proliferating tissues demonstrate transient pH Gradient Reversal i.e. alkalinization of pHi and acidification of pHe. [More]
New study aims to prevent chronic cardiac failure

New study aims to prevent chronic cardiac failure

Researchers at Osaka University clarified that the cell adhesion inhibition of periostin1 damages myocardinal cells, inducing compromised cardiac myocyte contractile force and myocytes death, leading to the onset of cardiac failure after AMI through the administration of periostin neutralizing antibodies they had developed on their own. [More]
Researchers use ASC secreted factors to create therapeutic factor concentrate for critical limb ischemia

Researchers use ASC secreted factors to create therapeutic factor concentrate for critical limb ischemia

"Critical limb ischemia" (CLI) describes an advanced stage of peripheral artery disease characterized by obstruction of the arteries and a markedly reduced blood flow to the extremities. CLI identifies patients at high-risk for major amputation. The estimated annual incidence of CLI ranges between 500 and 1000 new cases out of one million people per year, with the highest rates among the elderly, smokers, and those with diabetes. CLI is considered to be a critical public health issue. Attempts at revascularization are often unsuccessful. [More]
Common painkiller diclofenac has significant anti-cancer properties

Common painkiller diclofenac has significant anti-cancer properties

Diclofenac, a common painkiller, has significant anti-cancer properties, according to researchers from the Repurposing Drugs in Oncology project. [More]
New project aims to develop CAR-T cell immuno-oncology cellular therapy for solid tumours

New project aims to develop CAR-T cell immuno-oncology cellular therapy for solid tumours

The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, the University of Birmingham and Cancer Research Technology, the commercialisation arm of Cancer Research UK, announces today the launch of a collaboration to develop a new immuno-oncology cellular therapy based on gene modifying T cells to target solid tumours. [More]
Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited, its drug R&D subsidiary, has initiated SANET-ep, a Phase III sulfatinib (HMPL-012) registration trial in China in patients with extra-pancreatic neuroendocrine tumors ("NETs"), which are all non-pancreatic NETs, including, for example, NETs originating in the lymph, lung and across the gastrointestinal tract. [More]
Study sheds new light on the causes of autism

Study sheds new light on the causes of autism

Evidence of autism may be found in the composition and malfunction of the brain's blood vessels, a team of scientists has found. Their research sheds new light on the causes of autism, which previously had pointed to neurological make-up rather than to the vascular system, and identifies a new target for potential therapeutic intervention. [More]
Array BioPharma reports top-line results from binimetinib Phase 3 trial in patients with NRAS-mutant melanoma

Array BioPharma reports top-line results from binimetinib Phase 3 trial in patients with NRAS-mutant melanoma

Array BioPharma today reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial. The study met its primary endpoint of improving progression-free survival (PFS) compared with dacarbazine treatment. [More]
New therapeutic target can prevent abnormal blood vessel growth that causes gastrointestinal bleeding

New therapeutic target can prevent abnormal blood vessel growth that causes gastrointestinal bleeding

A study by IRB Barcelona and IDIBAPS reveals a therapeutic target to prevent the development of the many abnormal blood vessels that cause gastrointestinal bleeding—the main complication in cirrhosis. [More]
Myriad RBM's DiscoveryMAP platform identifies protein biomarkers linked to CV events in diabetes patients

Myriad RBM's DiscoveryMAP platform identifies protein biomarkers linked to CV events in diabetes patients

Myriad RBM, a wholly-owned subsidiary of Myriad Genetics, Inc., today announced that its DiscoveryMAP platform successfully identified combinations of 15 protein biomarkers associated with cardiovascular (CV) events or death in people with pre-diabetes or early type 2 diabetes, according to a study published by the journal Circulation. [More]
Tyrogenex announces results from phase 1 study of orally-administered X-82 in patients with AMD

Tyrogenex announces results from phase 1 study of orally-administered X-82 in patients with AMD

Tyrogenex, a privately held company focused on the development of targeted therapeutics for cancer and ophthalmology, today announced data from its phase 1 open-label study of orally-administered X-82 in patients for wet age-related macular degeneration (AMD). [More]
Pathophysiological biomarkers predict PAH prognosis

Pathophysiological biomarkers predict PAH prognosis

Researchers have identified three biomarkers that signify an increased risk of death or requirement for lung transplantation in patients with pulmonary arterial hypertension. [More]
New treatment may help patients with chronic renovascular disease

New treatment may help patients with chronic renovascular disease

A new treatment may help patients with a chronic kidney condition that can also lead to heart problems and premature death, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). [More]
Unwanted formation of blood vessels in the brain may cause intractable difficulties for Parkinson's disease patients

Unwanted formation of blood vessels in the brain may cause intractable difficulties for Parkinson's disease patients

Unwanted formation of blood vessels (angiogenesis) in the brain is likely to be the cause of intractable walking and balance difficulties for people who suffer from Parkinson's disease. This conclusion is supported by new research from Lund University in Sweden. [More]
Discovery offers promising alternative to current therapies for AMD and ROP

Discovery offers promising alternative to current therapies for AMD and ROP

A research team led by scientists at Beth Israel Deaconess Medical Center and the University of New Mexico School of Medicine has identified a small molecule that treats animal models of aged macular degeneration (AMD) and retinopathy of prematurity (ROP) by preventing the overgrowth of blood vessels that are characteristic of these two retinal diseases. [More]
Griffith University uncovers first 3-D image of protein linked to cancer spread

Griffith University uncovers first 3-D image of protein linked to cancer spread

Griffith University's Institute for Glycomics has made scientific history by determining the first three-dimensional image of a protein linked to the spread of cancer. [More]
NAM announces election of three new members from UC San Diego School of Medicine

NAM announces election of three new members from UC San Diego School of Medicine

The National Academy of Medicine announced today the election of three new members from University of California, San Diego School of Medicine: Napoleone Ferrara, MD; Christopher K. Glass, MD, PhD; and Roberto Malinow, MD, PhD. Election to NAM is considered among the highest honors in the fields of health and medicine. [More]
Novel ligand peptide-mimic inhibits abnormal overgrowth of blood vessels, may lead to new anti-cancer drugs

Novel ligand peptide-mimic inhibits abnormal overgrowth of blood vessels, may lead to new anti-cancer drugs

An international research team led by scientists at the University of New Mexico Cancer Center discovered and developed a novel ligand peptide-mimic that inhibits abnormal overgrowth of blood vessels in retinal diseases and tumors. The discovery could lead to new drugs that keep cancers from growing. The team published a paper in the journal Science Translational Medicine. [More]
Seno completes PIONEER Pivotal Study of non-invasive Imagio breast imaging system

Seno completes PIONEER Pivotal Study of non-invasive Imagio breast imaging system

Seno Medical Instruments, Inc., the company pioneering the development of opto-acoustic technology as a new tool to improve the process of diagnosing breast cancer, announced today it has completed the final phase of the company's U.S.-based PIONEER Pivotal Study of the Imagio® breast imaging system. [More]
Clinical trial data from Array BioPharma's binimetinib and encorafenib presented at ECC 2015

Clinical trial data from Array BioPharma's binimetinib and encorafenib presented at ECC 2015

Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients. [More]
Advertisement